<p>Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX - 免費報告）- HC Wainwright 的股票研究人員在 8 月 5 日星期二發佈的研究報告中下調了對 Praxis Precision Medicines 2029 財年的每股收益預期。HC Wainwright 分析師 D. Tsao 現在預計該公司將公佈每股收益為 21.43 美元，低於之前的 22.65 美元預期。HC Wainwright 目前對該股票的評級為 “買入”，目標價為 115.00 美元。市場普遍預計 Praxis Precision Medicines 當前全年的每股收益為（10.22 美元）。</p>
<p>Praxis Precision Medicines（納斯達克代碼：PRAX - 獲取免費報告）最近在 8 月 4 日星期一公佈了季度財報。該公司報告季度每股收益為（3.31 美元），超出分析師普遍預期的（3.40 美元）0.09 美元。Praxis Precision Medicines 的股本回報率為負的 59.42%，淨利潤率為負的 2,137.48%。</p>
<p>其他分析師最近也發佈了關於該公司的研究報告。Needham &amp; Company LLC 在 6 月 12 日星期四重申了 “買入” 評級，並對 Praxis Precision Medicines 的股票設定了 80.00 美元的目標價。Wedbush 將 Praxis Precision Medicines 的目標價從 26.00 美元上調至 28.00 美元，並在 5 月 5 日星期一的研究報告中給予該股票 “跑輸大盤” 的評級。Chardan Capital 在 7 月 29 日星期二的研究報告中重申了 “買入” 評級，並設定了 80.00 美元的目標價。最後，Oppenheimer 在 7 月 8 日星期二將 Praxis Precision Medicines 的目標價從 97.00 美元上調至 115.00 美元，並給予該股票 “跑贏大盤” 的評級。一位研究分析師對該股票給予了 “賣出” 評級，八位分析師則給予了 “買入” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 95.22 美元。</p>
<p><strong>查看我們關於 Praxis Precision Medicines 的最新股票報告</strong></p>
<h2>Praxis Precision Medicines 股價下跌 6.5%</h2>
<p>PRAX 股票在星期三開盤價為 47.79 美元。該股票的 50 日移動平均線為 47.56 美元，200 日移動平均線為 48.66 美元。Praxis Precision Medicines 的 12 個月低點為 26.70 美元，12 個月高點為 91.83 美元。該公司的市值為 9.7348 億美元，市盈率為 -3.89，貝塔係數為 2.62。</p>
<h2>對 Praxis Precision Medicines 的對沖基金看法</h2>
<p>幾家機構投資者最近買入和賣出了該公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第四季度將其在 Praxis Precision Medicines 的持倉增加了 2.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 11,135 股該公司的股票，價值 856,000 美元，此前在上個季度購買了 258 股。加利福尼亞州教師退休系統在第四季度將其在 Praxis Precision Medicines 的持倉增加了 2.2%。加利福尼亞州教師退休系統目前擁有 12,726 股該公司的股票，價值 979,000 美元，此前在上個季度購買了 275 股。Nisa Investment Advisors LLC 在第二季度將其在 Praxis Precision Medicines 的持倉增加了 88.3%。Nisa Investment Advisors LLC 目前擁有 629 股該公司的股票，價值 26,000 美元，此前在上個季度購買了 295 股。GF Fund Management CO. LTD. 在第四季度購買了 Praxis Precision Medicines 的新頭寸，價值 30,000 美元。最後，MetLife Investment Management LLC 在第四季度將其在 Praxis Precision Medicines 的持倉增加了 5.4%。MetLife Investment Management LLC 目前擁有 10,675 股該公司的股票，價值 822,000 美元，此前在上個季度購買了 544 股。機構投資者持有該公司 67.84% 的股份。</p>
<h2>Praxis Precision Medicines 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Praxis Precision Medicines, Inc. 是一家臨牀階段的生物製藥公司，專注於開發針對中樞神經系統疾病的治療，這些疾病的特徵是神經元興奮 - 抑制失衡。該公司正在開發 ulixacaltamide，這是一種 T 型鈣通道的小分子抑制劑，目前正在進行 III 期臨牀試驗，治療特發性震顫；PRAX-562 用於治療患有發育性和癲癇性腦病（DEE）的兒童患者；以及 PRAX-628 用於治療局灶性癲癇。</p>
<h2>另請參見</h2>
<ul>
<li>我們更看好的五隻股票，超過 Praxis Precision Medicines</li>
<li>投資者如何識別併成功交易下跌股票</li>
<li>三隻在財報超預期後火熱的行業 ETF</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>不尋常的機器：一種有助於提升其價格的投機</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>Zebra Technologies：乘着自動化浪潮獲利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Praxis Precision Medicines 嗎？</h2>
<p>在你考慮投資 Praxis Precision Medicines 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前... 而 Praxis Precision Medicines 並不在名單上。</p>
<p>雖然 Praxis Precision Medicines 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PRAX

<p>HC Wainwright 已將 Praxis Precision Medicines (NASDAQ:PRAX) 的 2029 財年每股收益預期從 $22.65 下調至 $21.43。該公司維持 “買入” 評級，目標價為 $115.00。市場對該公司當前全年的每股收益共識預期為 ($10.22)。Praxis 在上個季度報告的每股收益為 ($3.31)，超出預期。該股票在過去 12 個月的交易區間為 $26.70 至 $91.83，目前交易價格為 $47.79，下跌 6.5%。機構投資者持有 67.84% 的股份</p>

<p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities researchers at HC Wainwright lowered their FY2029 earnings per share estimates for shares of Praxis Precision Medicines in a research report issued on Tuesday, August 5th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $21.43 for the year, down from their prior estimate of $22.65. HC Wainwright currently has a &#34;Buy&#34; rating and a $115.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX - 免費報告）- HC Wainwright 的股票研究人員在 8 月 5 日星期二發佈的研究報告中下調了對 Praxis Precision Medicines 2029 財年的每股收益預期。HC Wainwright 分析師 D. Tsao 現在預計該公司將公佈每股收益為 21.43 美元，低於之前的 22.65 美元預期。HC Wainwright 目前對該股票的評級為 “買入”，目標價為 115.00 美元。市場普遍預計 Praxis Precision Medicines 當前全年的每股收益為（10.22 美元）。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($3.31) EPS for the quarter, topping analysts' consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative return on equity of 59.42% and a negative net margin of 2,137.48%.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（納斯達克代碼：PRAX - 獲取免費報告）最近在 8 月 4 日星期一公佈了季度財報。該公司報告季度每股收益為（3.31 美元），超出分析師普遍預期的（3.40 美元）0.09 美元。Praxis Precision Medicines 的股本回報率為負的 59.42%，淨利潤率為負的 2,137.48%。</p>
</div><p>Other analysts also recently issued research reports about the company. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. Wedbush raised their target price on Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an &#34;underperform&#34; rating in a research report on Monday, May 5th. Chardan Capital restated a &#34;buy&#34; rating and set a $80.00 target price on shares of Praxis Precision Medicines in a research report on Tuesday, July 29th. Finally, Oppenheimer raised their target price on Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $95.22.</p>
<div class="lb-trans"><p>其他分析師最近也發佈了關於該公司的研究報告。Needham &amp; Company LLC 在 6 月 12 日星期四重申了 “買入” 評級，並對 Praxis Precision Medicines 的股票設定了 80.00 美元的目標價。Wedbush 將 Praxis Precision Medicines 的目標價從 26.00 美元上調至 28.00 美元，並在 5 月 5 日星期一的研究報告中給予該股票 “跑輸大盤” 的評級。Chardan Capital 在 7 月 29 日星期二的研究報告中重申了 “買入” 評級，並設定了 80.00 美元的目標價。最後，Oppenheimer 在 7 月 8 日星期二將 Praxis Precision Medicines 的目標價從 97.00 美元上調至 115.00 美元，並給予該股票 “跑贏大盤” 的評級。一位研究分析師對該股票給予了 “賣出” 評級，八位分析師則給予了 “買入” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 95.22 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Praxis Precision Medicines 的最新股票報告</strong></p>
</div><h2>Praxis Precision Medicines Trading Down 6.5%</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股價下跌 6.5%</h2>
</div><p>Shares of PRAX stock opened at $47.79 on Wednesday. The stock has a 50 day moving average of $47.56 and a two-hundred day moving average of $48.66. Praxis Precision Medicines has a 12 month low of $26.70 and a 12 month high of $91.83. The company has a market capitalization of $973.48 million, a P/E ratio of -3.89 and a beta of 2.62.</p>
<div class="lb-trans"><p>PRAX 股票在星期三開盤價為 47.79 美元。該股票的 50 日移動平均線為 47.56 美元，200 日移動平均線為 48.66 美元。Praxis Precision Medicines 的 12 個月低點為 26.70 美元，12 個月高點為 91.83 美元。該公司的市值為 9.7348 億美元，市盈率為 -3.89，貝塔係數為 2.62。</p>
</div><h2>Hedge Funds Weigh In On Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>對 Praxis Precision Medicines 的對沖基金看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Praxis Precision Medicines by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,135 shares of the company's stock valued at $856,000 after purchasing an additional 258 shares during the last quarter. California State Teachers Retirement System raised its position in Praxis Precision Medicines by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 12,726 shares of the company's stock valued at $979,000 after purchasing an additional 275 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Praxis Precision Medicines by 88.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock valued at $26,000 after purchasing an additional 295 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Praxis Precision Medicines in the 4th quarter valued at $30,000. Finally, MetLife Investment Management LLC raised its position in Praxis Precision Medicines by 5.4% in the 4th quarter. MetLife Investment Management LLC now owns 10,675 shares of the company's stock valued at $822,000 after purchasing an additional 544 shares during the last quarter. Institutional investors own 67.84% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近買入和賣出了該公司的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第四季度將其在 Praxis Precision Medicines 的持倉增加了 2.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 11,135 股該公司的股票，價值 856,000 美元，此前在上個季度購買了 258 股。加利福尼亞州教師退休系統在第四季度將其在 Praxis Precision Medicines 的持倉增加了 2.2%。加利福尼亞州教師退休系統目前擁有 12,726 股該公司的股票，價值 979,000 美元，此前在上個季度購買了 275 股。Nisa Investment Advisors LLC 在第二季度將其在 Praxis Precision Medicines 的持倉增加了 88.3%。Nisa Investment Advisors LLC 目前擁有 629 股該公司的股票，價值 26,000 美元，此前在上個季度購買了 295 股。GF Fund Management CO. LTD. 在第四季度購買了 Praxis Precision Medicines 的新頭寸，價值 30,000 美元。最後，MetLife Investment Management LLC 在第四季度將其在 Praxis Precision Medicines 的持倉增加了 5.4%。MetLife Investment Management LLC 目前擁有 10,675 股該公司的股票，價值 822,000 美元，此前在上個季度購買了 544 股。機構投資者持有該公司 67.84% 的股份。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc. 是一家臨牀階段的生物製藥公司，專注於開發針對中樞神經系統疾病的治療，這些疾病的特徵是神經元興奮 - 抑制失衡。該公司正在開發 ulixacaltamide，這是一種 T 型鈣通道的小分子抑制劑，目前正在進行 III 期臨牀試驗，治療特發性震顫；PRAX-562 用於治療患有發育性和癲癇性腦病（DEE）的兒童患者；以及 PRAX-628 用於治療局灶性癲癇。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參見</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>3 Sector ETFs Catching Fire After Earnings Beats</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Unusual Machines: A Speculation With Tailwinds to Lift Its Price</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>Zebra Technologies: Riding the Automation Wave to Profits</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，超過 Praxis Precision Medicines</li>
<li>投資者如何識別併成功交易下跌股票</li>
<li>三隻在財報超預期後火熱的行業 ETF</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>不尋常的機器：一種有助於提升其價格的投機</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>Zebra Technologies：乘着自動化浪潮獲利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=PRAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Praxis Precision Medicines 嗎？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Praxis Precision Medicines 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前... 而 Praxis Precision Medicines 並不在名單上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Praxis Precision Medicines 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

HC Wainwright 對 Praxis Precision Medicines 2029 財年收益的估計是多少？